Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

days post last dose, Day 59 Table 4: ISIS 301012 Coadministered with Statins, Laboratory Findings. Number of patients with ALT elevations >/= 3xULN (maximal ALT observed = 211 IU/L). ALT Elevations Single(+) / Placebo 30 mg 100 mg 200 mg 300 mg 400 mg Consecutive(++) (n = 13) (n = 8) (n = 8) (n =16) (n = 8) (n = 8) Primary Endpoint (Day 1 to 59) 0 / 0 0 / 0 0 / 0 1 / 0 0 / 1 1 / 0 Primary Follow-up (Day 60 to 87) 0 / 0 0 / 0 0 / 0 0 / 1 0 / 0 0 / 0 Long term F/U (Day 88 to 199) 0 / 0 0 / 0 0 / 0 0 / 0 NA NA (+) Single = elevation that returned to below 3xULN by the next visit at least 7 days later (++) Consecutive = elevation that was observed in two measures at least 7 days apart Primary endpoint period was 30 days post last dose, Day 59 Primary follow-up period was from primary endpoint to 8 weeks post last dose NA = data not available, cohorts remain in follow-up Presentation Details Date: Monday, March 26, 2007 Session: 820: Clinical Trials of Lipid-Lowering Therapy (4:00 - 5:30 p.m. CT) Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Auditorium B Presentation: 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein Cholesterol and Apolipoprotein B in Hypercholesterolemic Subjects on Statins Not Meeting Target More about Phase 2 Trials for ISIS 301012

Additional data from two studies evaluating ISIS 301012's safety and lipid lowering activity were presented at the ACC. This morning in an ora
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
(Date:1/23/2015)... 23, 2015  Pete Rose, baseball,s all-time hits leader, is the ... reliever Myoflex, Ducere Pharma has announced. "Pete,s a ... to have him on board with Myoflex," said Ducere Pharma ... legendary player who is known across all generations. The passion ...
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Pete Rose bets on Myoflex to relieve aches and pains 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... ,, LAIYANG, China , July 9 /PRNewswire-Asia-FirstCall/ -- ... present at the Global Hunter Securities,China Investment Conference, which takes place July 11-13, 2010 ... , , ... 2010 , , , ...
... July 8 Sysmex, a global leader ... technology, today announced a three-year, dual source urinalysis ... purchasing/leasing access to Sysmex automated urine particle analyzers, ... for Amerinet members will be provided through Sysmex ...
Cached Medicine Technology:Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 2Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 3Sysmex America Announces Amerinet Urinalysis Contract 2Sysmex America Announces Amerinet Urinalysis Contract 3
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... DaVita,s Efforts in Corporate Social Responsibility and Support ... Calif., May 22 DaVita Inc. (NYSE: ... care services for those diagnosed with chronic kidney ... and marketing departments received eight Hermes Creative Awards, ...
... breast cancer had additional malignant tumors found only by ... Medical Center. , A total of 199 patients ... found additional, unsuspected cancers in the ipsilateral breast (the ... 16% of patients; we found cancers in the contralateral ...
... issued the,following press release: , ... flurry of panic about,the H1N1 (swine influenza). School ... even suggested closing the border with Mexico,where approximately three ... every day. The panic certainly was fueled by ...
... CyberKnife Centers Are Meeting Increasing Demand for ... TechnologiesSUNNYVALE, Calif., May 22 Accuray Incorporated ... leader in the field of radiosurgery, announced ... patient throughput using their recently installed, next ...
... Effort Addressing the Leading Cause of Maternal Mortality to ... Every year, more than half a million of the ... crisis that has seen little to no improvement over ... by Pathfinder International capitalized on groundbreaking new technologies in ...
... Reach $500 Million by 2014PRINCETON, N.J., May 22 ... federal funds next year and more than $500 million ... rules proposed to take effect in October, according to ... Economics department examined the impact of three provisions under ...
Cached Medicine News:Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 2Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 3Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 2Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 4Health News:New Initiative Poised To Reduce Maternal Mortality Rates By More Than 25 Percent 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 3
BD Vacutainer® Fluoride Tubes - Plastic...
Inquire...
Inquire...
... The inner wall of the serum ... particles, these particles activate the coagulation process. ... gel in the base of the tube; ... barrier between the serum and the blood ...
Medicine Products: